Pfizer Company Insiders

PFE Stock  USD 25.39  0.03  0.12%   
About 53% of Pfizer's corporate insiders are selling. The analysis of insiders' sentiment of trading Pfizer Inc stock suggests that many insiders are impartial at this time. Pfizer employs about 88 K people. The company is managed by 54 executives with a total tenure of roughly 367 years, averaging almost 6.0 years of service per executive, having 1629.63 employees per reported executive.
Ian Read  Chairman
Chairman, CEO and Chairman of Executive Committee
Douglas Lankler  President
Executive Vice President General Counsel

Pfizer's Insider Buying Vs Selling

47

 
Selling
 
Buying

Latest Trades

2024-02-12Earl BlumenauerAcquired @ 27.67
2023-12-28Jared MoskowitzDisposed @ 28.79
2023-12-20John BoozmanAcquired @ 27.63
2023-12-18Shelley Moore CapitoDisposed @ 27.05
2023-12-15Scott GottliebAcquired 3000 @ 26.47View
2023-12-14Jerry MoranDisposed @ 26.14
2023-12-12Kathy E. ManningDisposed @ 28.58
2023-12-11Sheldon WhitehouseDisposed @ 28.64
2023-10-24Greg StantonDisposed @ 30.43
2023-09-26Greg StantonAcquired @ 32.37
2023-09-11C. Scott FranklinDisposed @ 33.94
2023-09-08Lois FrankelDisposed @ 34.25
2023-07-25Tommy TubervilleAcquired @ 37.06
2023-07-12Daniel S. GoldmanDisposed @ 35.99
2023-06-28Lois FrankelAcquired @ 36.29
2023-06-12Tommy TubervilleAcquired @ 39.89
2023-05-26Zoe LofgrenDisposed @ 37.6
2023-05-08Scott GottliebAcquired 1000 @ 38.58View
2023-05-05Scott GottliebAcquired 1000 @ 38.42View
Monitoring Pfizer's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Pfizer's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Pfizer Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Pfizer's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

Pfizer's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pfizer's future performance. Based on our forecasts, it is anticipated that Pfizer will maintain a workforce of about 90000 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Pfizer's latest congressional trading

Congressional trading in companies like Pfizer Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Pfizer by those in governmental positions are based on the same information available to the general public.
2024-02-27Senator Thomas H TubervilleAcquired Under $15KVerify
2024-02-12Representative Earl BlumenauerAcquired Under $15KVerify
2023-12-20Senator John BoozmanAcquired Under $15KVerify
2023-12-18Senator Shelley M CapitoAcquired Under $15KVerify
2023-12-11Senator Sheldon WhitehouseAcquired Under $15KVerify
2023-10-24Representative Greg StantonDisposed Under $15KVerify
2023-09-11Representative C. Scott FranklinDisposed $15K to $50KVerify
2023-03-03Representative Carol Devine MillerAcquired Under $15KVerify
2023-01-11Representative Michael Patrick GuestDisposed Under $15KVerify
2021-12-21Senator Jerry MoranAcquired Under $15KVerify
2021-08-16Representative Mo BrooksDisposed $15K to $50KVerify
2021-07-14Representative Richard W. AllenAcquired $15K to $50KVerify
2021-02-16Representative Peter MeijerDisposed $15K to $50KVerify
2020-07-09Senator Thomas R. CarperAcquired Under $15KVerify
2020-07-01Representative K. Michael ConawayAcquired $15K to $50KVerify
2020-04-07Senator Kelly LoefflerAcquired $100K to $250KVerify
2020-02-28Senator David A Perdue , JrAcquired Under $15KVerify
2019-02-05Representative Donna ShalalaDisposed Under $15KVerify
2018-06-04Senator Susan M. CollinsAcquired Under $15KVerify
2017-09-05Senator Shelley Moore CapitoAcquired Under $15KVerify

Pfizer Management Team Effectiveness

The company has Return on Asset of 0.0155 % which means that on every $100 spent on assets, it made $0.0155 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0235 %, implying that it generated $0.0235 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.
The current year's Common Stock Shares Outstanding is expected to grow to about 6 B. The current year's Net Income Applicable To Common Shares is expected to grow to about 37.9 B

Pfizer Workforce Comparison

Pfizer Inc is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 92,664. Pfizer totals roughly 88,000 in number of employees claiming about 95% of equities under Health Care industry.

Pfizer Profit Margins

The company has Net Profit Margin of 0.04 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of (0.5) %, which entails that for every $100 of revenue, it lost $0.5.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.5006
Fairly Up
Slightly volatile
Net Profit Margin0.03440.0362
Notably Down
Pretty Stable
Operating Profit Margin0.06880.0724
Notably Down
Slightly volatile
Pretax Profit Margin0.01720.0181
Notably Down
Pretty Stable
Return On Assets0.00890.0094
Notably Down
Pretty Stable
Return On Equity0.02260.0238
Notably Down
Pretty Stable

Pfizer Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pfizer insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
1.2045
53
44
 4,240,517 
 854,465 
2023-09-01
25.0
25
1
 6,026 
 0.00 
2023-06-01
39.0
39
1
 100,638 
 16,223 
2023-03-01
1.0
57
57
 2,792,894 
 1,048,653 
2022-12-01
10.3333
31
3
 407,055 
 368,604 
2022-06-01
7.125
57
8
 373,722 
 117,822 
2022-03-01
0.9143
64
70
 3,135,600 
 1,833,982 
2021-12-01
0.6324
43
68
 419,133 
 1,264,052 
2021-09-01
8.5
34
4
 48,193 
 4,161 
2021-06-01
14.6667
44
3
 65,772 
 16,080 
2021-03-01
0.8933
67
75
 4,637,604 
 2,656,850 
2020-12-01
8.75
35
4
 23,582 
 187,438 
2020-06-01
2.8421
54
19
 78,317 
 208,381 
2020-03-01
0.9663
86
89
 5,142,206 
 2,546,317 
2019-12-01
7.0
35
5
 6,301 
 12,048 
2019-09-01
2.05
41
20
 135,265 
 153,184 
2019-06-01
1.6154
42
26
 52,465 
 49,495 
2019-03-01
0.3782
104
275
 6,153,830 
 4,978,791 
2018-12-01
8.6
43
5
 1,105,760 
 2,247,006 
2018-09-01
0.5625
36
64
 204,666 
 1,150,678 
2018-06-01
2.6429
37
14
 63,402 
 185,435 
2018-03-01
0.466
48
103
 2,406,461 
 2,174,116 
2017-12-01
2.5
10
4
 3,234 
 29,450 
2017-09-01
1.1111
10
9
 3,282 
 184,543 
2017-03-01
1.0
37
37
 1,663,656 
 970,676 
2016-12-01
2.3333
21
9
 123,417 
 305,355 
2016-06-01
0.3784
28
74
 432,268 
 1,013,128 
2016-03-01
0.9459
35
37
 1,637,202 
 994,616 
2015-12-01
17.0
17
1
 4,752 
 2,520 
2015-09-01
17.0
17
1
 4,759 
 1,000.00 
2015-06-01
3.1111
28
9
 105,948 
 104,503 
2015-03-01
0.4536
44
97
 1,417,708 
 1,258,003 
2014-12-01
0.9355
29
31
 199,816 
 566,489 
2014-09-01
23.0
23
1
 8,650 
 1,064 
2014-06-01
5.2
26
5
 84,691 
 61,859 
2014-03-01
0.6625
53
80
 1,878,990 
 1,541,140 
2013-12-01
2.6471
45
17
 144,037 
 243,869 
2013-09-01
5.1
51
10
 169,328 
 266,600 
2013-06-01
2.4286
51
21
 38,972 
 100,193 
2013-03-01
0.8197
50
61
 2,085,489 
 1,401,415 
2012-12-01
5.5
33
6
 4,394 
 37,020 
2012-09-01
4.625
37
8
 4,692 
 121,517 
2012-06-01
52.0
52
1
 53,188 
 19,670 
2012-03-01
3.2143
45
14
 2,221,652 
 193,363 
2011-12-01
9.0
45
5
 19,412 
 13,403 
2011-09-01
15.0
45
3
 10,613 
 35,318 
2011-06-01
25.5
51
2
 92,513 
 20,993 
2011-03-01
2.0
40
20
 1,616,922 
 99,233 
2010-12-01
1.3929
39
28
 8,799 
 811,350 
2010-09-01
18.5
37
2
 7,401 
 43,498 
2010-06-01
6.25
50
8
 53,762 
 41,614 
2010-03-01
4.6667
28
6
 1,827,967 
 203,031 
2009-12-01
10.75
43
4
 196,639 
 849.00 
2009-09-01
5.1429
36
7
 102,142 
 200,049 
2009-06-01
21.0
42
2
 50,384 
 13,600 
2009-03-01
3.2727
36
11
 2,303,199 
 505,602 
2008-09-01
50.0
50
1
 11,047 
 38,281 
2008-06-01
25.0
50
2
 283,066 
 10,000 
2008-03-01
7.6
38
5
 1,559,094 
 8,823 
2007-12-01
2.5833
31
12
 157,834 
 533,556 
2007-09-01
34.0
34
1
 533,595 
 0.00 
2007-06-01
5.125
41
8
 161,210 
 104,699 
2007-03-01
2.0667
31
15
 1,762,307 
 319,994 
2006-12-01
11.0
44
4
 12,115 
 16,146 
2006-09-01
1.56
39
25
 858,671 
 1,182,426 
2006-06-01
4.1
41
10
 248,777 
 399,464 
2006-03-01
2.9
29
10
 2,936,362 
 68,156 
2005-12-01
7.8
39
5
 8,765 
 59,925 
2005-09-01
19.5
39
2
 357,042 
 655,520 
2005-06-01
6.125
49
8
 44,346 
 126,934 
2005-03-01
1.2
24
20
 2,336,955 
 1,067,511 
2004-12-01
9.2
46
5
 9,714 
 63,616 
2004-09-01
47.0
47
1
 26,088 
 17,508 
2004-06-01
21.0
63
3
 53,623 
 7,896 
2004-03-01
2.3529
40
17
 1,974,456 
 865,954 
2003-12-01
5.2222
47
9
 71,159 
 135,061 
2003-09-01
20.5
41
2
 25,054 
 19,105 

Pfizer Notable Stakeholders

A Pfizer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pfizer often face trade-offs trying to please all of them. Pfizer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pfizer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Albert DVMChairman CEOProfile
Ian ReadChairman, CEO and Chairman of Executive CommitteeProfile
Douglas LanklerExecutive Vice President General CounselProfile
Mikael DolstenChief Scientific Officer, President - Worldwide Research, Development and MedicalProfile
Lidia FonsecaExecutive Vice President, Chief Technology Officer and Digital OfficerProfile
Geno GermanoGroup President of Global Innovative Pharma Bus.Profile
Laurie OlsonExecutive Vice President - Strategy, Portfolio and Commercial OperationsProfile
Rady JohnsonChief Compliance, Quality and Risk Officer, Executive Vice PresidentProfile
Charles HillExecutive Vice President - Worldwide Human ResourcesProfile
Albert BourlaGroup President - Vaccines, Oncology and Consumer Healthcare BusinessProfile
Payal SahniExecutive Vice President, Chief People Experience OfficerProfile
Kirsten LundJurgensenExecutive Vice President and Presidentident - Pfizer Global SupplyProfile
Angela HwangGroup President - Pfizer Biopharmaceuticals GroupProfile
Kathrin JansenSenior Vice President - Vaccine Research & DevelopmentProfile
John YoungGroup President - Pfizer Innovative Health and Angela HwangProfile
Frank DAmelioChief Financial Officer, Executive Vice President - Business Operations and Global SupplyProfile
Dawn RogersChief Human Resource Officer, Executive Vice PresidentProfile
Alexander MackenzieExecutive Vice President Chief Development OfficerProfile
Sally SusmanChief Corporate Affairs Officer, Executive Vice PresidentProfile
Anthony MaddalunaExecutive Vice President and Presidentident - Pfizer Global SupplyProfile
Freda LewisHallExecutive Vice President Chief Medical OfficerProfile
Michael GoettlerGroup President - Pfizer UpjohnProfile
Shantanu NarayenLead Independent DirectorProfile
Susan DesmondHellmannIndependent DirectorProfile
Stephen SangerIndependent DirectorProfile
James QuinceyIndependent DirectorProfile
Helen HobbsIndependent DirectorProfile
James SmithIndependent DirectorProfile
Dennis AusielloIndependent DirectorProfile
Frances FergussonIndependent DirectorProfile
Wyllie CornwellIndependent DirectorProfile
Suzanne JohnsonIndependent DirectorProfile
Susan HockfieldIndependent DirectorProfile
Dan LittmanIndependent DirectorProfile
James KiltsIndependent DirectorProfile
Don CornwellIndependent DirectorProfile
Joseph EchevarriaIndependent DirectorProfile
Scott GottliebIndependent DirectorProfile
Ronald BlaylockIndependent DirectorProfile
Payal BecherChief VPProfile
Jennifer DamicoSenior Vice President Principal Accounting Officer, ControllerProfile
Aamir MalikExecutive Vice President Chief Business Innovation OfficerProfile
Christopher StevoSenior Vice President and Chief Investor Relations OfficerProfile
William CarapezziExecutive Vice President - Global Business Services and TransformationProfile
Mikael MDChief DevelopmentProfile
Mike McdermottExecutive Vice President Chief Global Supply OfficerProfile
Christopher CFAVP OfficerProfile
Michael McdermottExecutive Vice President Chief Global Supply OfficerProfile
Francesca DeMartinoChief OfficerProfile
Gordon LohSenior Vice President Corporate AuditProfile
David DentonChief VPProfile
DVM DVMChairman CEOProfile
William GrayIndependent DirectorProfile
Andreas PanayiotouGlobal OfficerProfile

About Pfizer Management Performance

The success or failure of an entity such as Pfizer Inc often depends on how effective the management is. Pfizer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pfizer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pfizer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.02  0.02 
Return On Capital Employed 0.02  0.02 
Return On Assets 0.01  0.01 
Return On Equity 0.02  0.02 
The data published in Pfizer's official financial statements usually reflect Pfizer's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Pfizer Inc. For example, before you start analyzing numbers published by Pfizer accountants, it's critical to develop an understanding of what Pfizer's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Pfizer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pfizer Inc. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.

Pfizer Workforce Analysis

Traditionally, organizations such as Pfizer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pfizer within its industry.

Pfizer Manpower Efficiency

Return on Pfizer Manpower

Revenue Per Employee664.7K
Revenue Per Executive1.1B
Net Income Per Employee24.2K
Net Income Per Executive39.5M
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stocks Directory
Find actively traded stocks across global markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Dividend Share
1.64
Earnings Share
0.37
Revenue Per Share
10.366
Quarterly Revenue Growth
(0.41)
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.